ISTITUTO SUPERIORE DI SANITA [ ISS ]

Viale Regina Elena 299 00161 ROMA - Italy

Ms Rosa Maria Martoccia

dirgensa@iss.it +390649906057 Website

Involved in the following projects during the 3rd programme

3rd Health Programme (2014-2020)
Managing Frailty. A comprehensive approach to promote a disability-free advanced age in Europe: the ADVANTAGE initiative [ADVANTAGE]
Managing Frailty. A comprehensive approach to promote a disability-free advanced age: the ADVANTAGE initiative
ADVANTAGE will build a common understanding on frailty to be used by Member States on...
Managing Frailty. A comprehensive approach to promote a disability-free advanced age: the ADVANTAGE initiative
ADVANTAGE will build a common understanding on frailty to be used by Member States on which to base a common management approach of older people who are frail or at risk for developing frailty in the European Union.
The identification of the core components of frailty and its management should promote the needed changes in the organization and the implementation of the Health and Social Systems to provide those models of care that, stemming from the particular health profile of each Member State (MS), will allow them to face the challenge of frailty within a common framework.
ADVANTAGE will summarise the current State of the Art for the different components of frailty and its management, both at individual and population level, will collect information on the development of programs to manage frailty in older adults in the EU and will propose, as its main outcome, a common European model to approach frailty. This model will include a road map that, considering the degree of frailty policies� development, will propose interventions for frail and at risk people and will establish tailored milestones for each MS in order to achieve a comprehensive approach to promote a disability-free advanced age. Furthermore, the model will identify gaps of knowledge in the field that would benefit from further research.
Start date: 01/01/2017 - End date: 31/12/2019
Keywords : [ Ageing ] [ Frailty ] [ Function ]

Call: Health Programme Adhoc Call for invited (named) beneficiaries
Topic: Prevention of frailty
3rd Health Programme (2014-2020)
Joint Action on Dementia 2015-2018 [DEM 2]
Joint Action on Dementia 2015-2018The Joint Action will focus on two phases on work: approximately 12 months on developing a consensus on the best evidence of effective action in 4 key areas (diagnosi...
Joint Action on Dementia 2015-2018The Joint Action will focus on two phases on work: approximately 12 months on developing a consensus on the best evidence of effective action in 4 key areas (diagnosis and post-diagnostic support; crisis and care coordination; quality of care in residential care settings; and dementia-friendly communities); and approximately 24 months on testing the best evidence of effective action in localities to develop a greater understanding of how change can be taken forward in practice.In addition, there will be 3 additional components: evaluation of the joint action (outputs and quality: dissemination; and overall coordination of this project.The project will be achieved through collaborative effort, with the 4 main work plans having identified leads or co-leads and other countries contributing time to the work.
Start date: 01/03/2016 - End date: 31/10/2019

Call: Grants for actions co-financed with Member State authorities 2014 (Joint Actions)
Topic: Dementia Joint Action
3rd Health Programme (2014-2020)
Information for Action [InfAct]
InfAct (Information for Action) is a JA on health information (HI). HI is essential to build up country specific and cross-country knowledge. HI is the basis to inform national health policies, to ste...
InfAct (Information for Action) is a JA on health information (HI). HI is essential to build up country specific and cross-country knowledge. HI is the basis to inform national health policies, to steer population health investment decisions, to assess the effectiveness of different approaches to enhance population health through promotion, prevention, treatments and care. Timely, up-to-date HI is also vital in framing EU wide programs and policies.

The major outcome expected of the JA is a sustainable solid infrastructure on EU HI through improving the availability of comparable, robust and policy-relevant health status data and health system performance information. Through country collaboration, the JA streamlines HI activities, reduces the data collection burden and works for a sustainable and robust data collection in Europe that facilitates and supports country knowledge, health research and policy making.

The JA gives attention to:

• develop the business case and roadmap for implementation of the European Research Infrastructure Consortium on Health Information for Research and Evidence-based Policy
o governance structures,
o national HI consortia and domain specific HI research networks
• assess HI systems (HIS) in MS and regions
• develop a roadmap for training in HI with the objective to tackle HI inequality through Europe
• standardize HI instruments, tools and methods
• strengthen the HI efficiency for public health policy through new ways of using health and non-health data sources
• enhance the introduction of the interoperability of health data sources
• enhance the translation of HI into public policy

The JA watches for the sustainability of all actions taken by the JA. Coordination, dialogue and interaction with the Commission Expert Groups on HI and on HSPA, Eurostat, DG Research and other relevant DGs, international organization (WHO, OECD) reinforce further the sustainability of the JAs’ work and outcomes.

Start date: 01/03/2018 - End date: 28/02/2021

Call: Joint Actions 2017
Topic: Joint Action on Health Information towards a sustainable EU health information system that supports country knowledge, health research and policy-making.
3rd Health Programme (2014-2020)
Commmon Approach for REfugees and other migrants' health [CARE]

Since 2011 the geopolitical instability in the Middle East and North Africa has been contributing to exceptional flows of migrants to South European countries. According to IOM estimates, 769,399 ref...

Since 2011 the geopolitical instability in the Middle East and North Africa has been contributing to exceptional flows of migrants to South European countries. According to IOM estimates, 769,399 refugees and migrants crossed the Mediterranean Sea to reach Italy, Greece and Malta during the period 1 January - 6 November 2015. WHO does not recommend obligatory screening of refugee and migrant populations for diseases, because there is no clear evidence of benefits but strongly recommends offering and providing health checks at the entry points to ensure access to health care for all refugees and migrants in need of health protection, specific population groups (children, pregnant women, elderly) included. But migrant’s health deserves to be profoundly understood and clinical attitude accordingly adapted. That’s why migrants’ health needs are at the very centre of the today discussion and multidisciplinary teams identified as the most appropriate approach to tackle them. This model results to be effective particularly in approaching even more fragile subgroups, such as minors, pregnant women and victims of violence. The project, which can count upon the endorsement of 5 MS governments experiencing strong migration flows, deploys its potential throughout 8 WPs, all tailored addressing different aspects of migrant’s health, with a view to hosting societies. Among them, three WPs are horizontal, namely coordination, results dissemination and evaluation. Other WPs do sustain the health of migrants within the hotspots and migrants’ centres, produce evidence based instruments to manage health threats and syndromic surveillance, offer a way for tracking migrant’s health on the move, produces training and information material for health staff and general public as well as intervene into the public/private relationships to promote a new governance model for migration public policies.
Start date: 01/04/2016 - End date: 31/03/2017

Call: Support Member States under particular migratory pressure in their response to health related challenges
Topic: Support Member States under particular migratory pressure in their response to health related challenges
3rd Health Programme (2014-2020)
Good Practices for demonstrating safety and quality through recipient follow-up [Euro-GTP II]
The main objective of this project is to set up the good practices applied to tissues and cells (T&C) preparation processes and patient follow-up procedures, to ensure their safe and effective impleme...
The main objective of this project is to set up the good practices applied to tissues and cells (T&C) preparation processes and patient follow-up procedures, to ensure their safe and effective implementation.
The outputs of this project will provide tools for assessing and verifying the quality, promote safety and assure efficacy of therapies with human tissues, Hematopoietic Stem Cells (HSC) and Assisted Reproductive Technologies (ART), addressing mainly to the implementation of novel T&C preparation processes and clinical indications, but also to the need of retrospective studies where weaknesses or insufficient safety data currently exist.
Recommendations will be forwarded to Tissue Establishments (TE) and Organizations Responsible for Human Application (ORHA), as the main actors in the process of validation and designing T&C preparation processes and patient follow-up according to a clinical indication.
This project aim to define the threshold of novelty, including definition of the factors that should be considered to determine the scope and depth of the clinical follow-up studies needed. The scope and extent of the recommended studies will be determined on the basis of a risk based approach performed taking into account factors such as the novelty of the product/preparation process/clinical indication, and its technical complexity.
A T&C Database of products, preparation procedures, clinical applications and their current status of authorisation and implementation will be established, working as a starting point for determining the ‘novelty’ of processes/therapies by TEs and ORHAs, and allowing the use of established processes/therapies by any centre that strictly follows the same procedure/clinical procedure/indication.
This project also aims to define a “GTP’s management model” that could provide impetus for future standards harmonisation and promotion, and allow the establishment of European accreditation and training programs for TE.
Start date: 01/04/2016 - End date: 31/03/2019

Call: Call for Proposals for Projects 2015
Topic: Common assessment methodology on quality, safety and efficacy of transplantation therapies
3rd Health Programme (2014-2020)
Innovative Partnership for Action Against Cancer [iPAAC]
The general objective of the Joint Action – Innovative Partnership for Action Against Cancer (iPAAC JA) is to develop innovative approaches to advances in cancer control. The innovation that will be...
The general objective of the Joint Action – Innovative Partnership for Action Against Cancer (iPAAC JA) is to develop innovative approaches to advances in cancer control. The innovation that will be covered within the JA consists of further development of cancer prevention, comprehensive approaches to the use of genomics in cancer control, cancer information and registries, improvements and challenges in cancer care, mapping of innovative cancer treatments and governance of integrated cancer control, including a new analysis of National Cancer Control Plans. The development of innovative approaches to cancer control will be supplemented by a Roadmap on Implementation and Sustainability of Cancer Control Actions, which will support Member States in implementation of iPAAC and CANCON recommendations. The Roadmap will act as the central pillar of the JA, integrating the diverse topic areas, providing synergies between the topics, ensuring consideration of transversal issues for all topics and acting as the central comprehensive deliverable, integrating all the JA outputs. A variety of methods will be used to fulfil the general and specific objectives including pilot studies, working groups, expert panels, literature review and surveys. A governmental board will be in place to ensure that implementation and sustainability in national contexts are duly considered for each topic area. The proposal for the iPAAC JA proposes actions to address objective 1 of the 2017 annual work programme, that is promoting health, preventing diseases and fostering supportive environments for healthy lifestyles taking into account the ‘health in all policies’ principle. The work to be developed by the iPAAC JA is complementary to the outcomes of the EPAAC and CANCON Joint Actions, funded by the Second and Third Health Programmes and will build on their outputs, using the stakeholder networks as an optimal base for the development of innovative cancer control actions.
Start date: 01/04/2018 - End date: 31/03/2021

Call: Joint Actions 2017
Topic: Joint Action — Innovative Partnership on Action against Cancer
3rd Health Programme (2014-2020)
BRidging Information and Data Generation for Evidence-based Health Policy and Research [BRIDGE Health]
BRIDGE Health (BRidging Information and Data Generation for Evidence-based Health Policy and Research) aims to create European health information (EU-HI) and data generation networks covering major EU...
BRIDGE Health (BRidging Information and Data Generation for Evidence-based Health Policy and Research) aims to create European health information (EU-HI) and data generation networks covering major EU health policy areas. The network uses comprehensive experience and assures a knowledge transfer from past health and research frameworks.

The aim is to work towards a comprehensive, integrated and sustainable EU-HI supporting evidence-based health policy and research for the EU and Member States by providing blueprints and/or concepts of building blocks for a future EU-HI research infrastructure consortium (ERIC-HI).

The project bridges key EU projects in domains of population and health system monitoring and indicator development, health examination surveys, environment and health, population injury and disease registries, clinical and administrative health data collection systems and methods of health system monitoring and evaluation.

The project aims to:
1) enhance the transferability of health information and data for policy and improve the utility and use of data and indicators for stakeholders in policy making, public health surveillance and health care;
2) reduce health information inequality within the EU and within MS;
3) develop a blueprint for a sustainable and integrated EU Health information system by developing common methods for a) standardising the collection and exchange of health information within and between domains, between MS, including e-health platforms; b) ensuring data quality, including procedures for internal and external validation of health indicators; c) undertaking priority setting exercises for health information, d) addressing ethical and legal issues associated with the collection and use of health data within MS and the EU.

Coordination, dialogue and interaction with DG-SANCO, the Expert Group on Health Information, Eurostat, DG Research and other DGs ensure the sustainability of the work and bridges to a future ERIC-HI.
Start date: 01/05/2015 - End date: 31/10/2017
Call: Call for Proposals for Projects 2014
Topic: Health monitoring and reporting system
3rd Health Programme (2014-2020)
facilitatinG the Authorisation of Preparation Process for blood and tissues and cells [GAPP]
GAPP Joint Action (facilitatinG the Authorisation of Preparation Process for blood and tissues and cells) is a 36 months JA aiming at facilitating the development of a common and optimal approach to a...
GAPP Joint Action (facilitatinG the Authorisation of Preparation Process for blood and tissues and cells) is a 36 months JA aiming at facilitating the development of a common and optimal approach to assess and authorise preparation processes in blood and tissues establishments (BEs and TEs). Particular attention will be devoted to innovative processes that might come up taking advantage of the work developed in previous EU funded projects/actions. This Joint Action will clearly contribute to the implementation of Union legislation in the fields of human tissues and cells, blood, providing tools and training to increase harmonisation of those MS activities that regulate the areas of blood transfusion, transplantation of tissues and cells and assisted reproduction, in strong abidance with art 4.5 of Annex I of Regulation 282/2014. These are fields of healthcare that involve a considerable amount of movement of donated substances of human origin between MS and also movement of citizens between MS for treatment, particularly in the field of assisted reproduction. The aim of the action is to prepare a “Good Practice Guidelines to authorisation and preparation process in blood, tissues and cells” and its three technical annexes respectively on i) authorisation changes in donation, procurement and collection, processing, preservation, storage and distribution (divided in three part blood, tissues and cells, and reproductive tissues and cells); ii) assessing the quality and safety of donor testing, microbial inactivation and sterilisation steps as part of PPA; iii) assessing clinical data as part of PPA. In addition to this it will be built a model and a tool to facilitate sharing of information among European Union Competent Authorities and a number of CA inspectors will be trained specifically to assess and authorise preparation processes of tissues, cells, reproductive cells and blood products.
Start date: 01/05/2018 - End date: 30/04/2021

Call: Joint Actions 2016
Topic: Authorisation of preparation processes in blood and tissues and cells
3rd Health Programme (2014-2020)
Efficient response to highly dangerous and emerging pathogens at EU level [EMERGE]
The human population is confronted with emerging and re-emerging infectious pathogens that can cause serious cross-border outbreaks. A recent example is the Ebola outbreak requiring strong diagnostic,...
The human population is confronted with emerging and re-emerging infectious pathogens that can cause serious cross-border outbreaks. A recent example is the Ebola outbreak requiring strong diagnostic, clinical, and public health measures in Europe and abroad in order to get this incident under control. The JA EMERGE is in compliance with the European policy (Decision No 1082/2013/EU) where the need for an efficient, rapid and coordinated response to high threat pathogens is defined. The JA EMERGE comprises a European network with more then 40 diagnostic laboratories focused on risk group 3 bacteria and risk groups 3 and 4 viruses. It will act in a so-called inter-epidemic mode (IEM) which can be activated and switched into an outbreak response mode (ORM) on request by the Health Security Committee in order to direct all activities to the outbreak management. A number of other laboratory networks, institutions and agencies are contributing to the management of cross-border infectious outbreaks. EMERGE will provide a platform for establishment and consolidation of a common, coordinated and effective response to infectious disease outbreaks at EU level and abroad (WP4). State of the art and new diagnostic methods for high threat pathogens, including in-house and commercial kits, will be evaluated for their applicability and recommended in outbreak situations when suitable (WP5). External quality assurance exercises will ensure best approaches for laboratory responsiveness in outbreak situations (WP6). These activities must be supported by an appropriate training to share best practices of diagnostics and bio-risk management (WP7). In conclusion, the general objective will be to ensure efficient response to serious emergent and re-emergent cross-border events by reinforcing the existing EU network of BSL 3 and BSL 4 laboratories which are already active in the field of identification of dangerous bacterial and viral human pathogens.
Start date: 01/06/2015 - End date: 31/01/2019

Call: Grants for actions co-financed with Member State authorities 2014 (Joint Actions)
Topic: Pathogens Joint Action
3rd Health Programme (2014-2020)
Promoting Implementation of Recommendations on Policy, Information and Data for Rare Diseases [RD-ACTION]
Rare diseases (RD) have been identified as one of the paradigmatic fields in which actions conducted at the European level constitute the adequate response to their specific problems: poor recognition...
Rare diseases (RD) have been identified as one of the paradigmatic fields in which actions conducted at the European level constitute the adequate response to their specific problems: poor recognition leading to diagnostic delay and inappropriate management including adapted social services, poor health outcomes, social burden, limited knowledge on natural history and pathophysiology leading to an insufficient development of new therapies. The low prevalence and the specificity of RD make that a global, multi-stakeholder approach, intended to gather specific expertise and to build shared strategies is necessary to address these issues.
The general objectives of RD-Action are to:
▪ Support the further development and sustainability of the Orphanet database, the biggest global repository of information on RD
▪ Contribute to solutions to ensure an appropriate codification of RD in health information systems
▪ Continue implementation of the priorities identified in Council Recommendation 2009/C151/02 and the Commission Communication (COM 2008 679) on RD, with a view to ensuring the sustainability of the recommended priority actions and to support the work of the Commission Expert Group on Rare Diseases (CEGRD).
This JA will expand and consolidate the achievements of the former JAs on RD supported by the European Commission: the Orphanet JA and the EUCERD JA. More precisely, this proposal has the ambition to help member states to implement the recommended measures adopted or to be adopted by the CEGRD and to produce the data necessary for countries to do so. Interactions between the production of data at the Orphanet database level and the implementation of policy priorities including codification will be strengthened during this JA.RD-Action large geographical coverage is key to success as it will promote the transfer of European recommendations into national policies and the collection of information and concerns from MS to the CEGRD, thus to the European Commission.

Start date: 01/06/2015 - End date: 31/07/2018

Call: Grants for actions co-financed with Member State authorities 2014 (Joint Actions)
Topic: Rare Disease Joint Action